Trial · NCT04425902
Adverse events36
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 36
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Dizziness | Nervous system disorders | Treatment A: Probe Substrates | 0 | 20 | |
| other | Dizziness | Nervous system disorders | Treatment B: GSK3640254 200 mg | 3 | 20 | |
| other | Dizziness | Nervous system disorders | Treatment C: Probe Substrates + GSK3640254 200 mg | 0 | 19 | |
| other | Headache | Nervous system disorders | Treatment A: Probe Substrates | 1 | 20 | |
| other | Headache | Nervous system disorders | Treatment B: GSK3640254 200 mg | 1 | 20 | |
| other | Headache | Nervous system disorders | Treatment C: Probe Substrates + GSK3640254 200 mg | 1 | 19 | |
| other | Taste disorder | Nervous system disorders | Treatment A: Probe Substrates | 0 | 20 | |
| other | Taste disorder | Nervous system disorders | Treatment B: GSK3640254 200 mg | 0 | 20 | |
| other | Taste disorder | Nervous system disorders | Treatment C: Probe Substrates + GSK3640254 200 mg | 1 | 19 | |
| other | Nausea | Gastrointestinal disorders | Treatment A: Probe Substrates | 0 | 20 | |
| other | Nausea | Gastrointestinal disorders | Treatment B: GSK3640254 200 mg | 1 | 20 | |
| other | Nausea | Gastrointestinal disorders | Treatment C: Probe Substrates + GSK3640254 200 mg | 1 | 19 | |
| other | Abdominal discomfort | Gastrointestinal disorders | Treatment A: Probe Substrates | 0 | 20 | |
| other | Abdominal discomfort | Gastrointestinal disorders | Treatment B: GSK3640254 200 mg | 0 | 20 | |
| other | Abdominal discomfort | Gastrointestinal disorders | Treatment C: Probe Substrates + GSK3640254 200 mg | 1 | 19 | |
| other | Diarrhoea | Gastrointestinal disorders | Treatment A: Probe Substrates | 0 | 20 | |
| other | Diarrhoea | Gastrointestinal disorders | Treatment B: GSK3640254 200 mg | 1 | 20 | |
| other | Diarrhoea | Gastrointestinal disorders | Treatment C: Probe Substrates + GSK3640254 200 mg | 0 | 19 | |
| other | Dermatitis contact | Skin and subcutaneous tissue disorders | Treatment A: Probe Substrates | 0 | 20 | |
| other | Dermatitis contact | Skin and subcutaneous tissue disorders | Treatment B: GSK3640254 200 mg | 0 | 20 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04425902/events